Mechanism of action of formononetin in alleviating allergic asthma through DRP1-NLRP3 signaling pathway
- Author:
Mu CHEN
1
;
Qiao-Yun BAI
1
;
Yi-Lan SONG
1
;
Jiao CHEN
1
;
Yong-De JIN
1
;
Guang-Hai YAN
1
;
Jiao CHEN
2
;
Yong-De JIN
2
;
Qiao-Yun BAI
3
;
Yi-Lan SONG
3
;
Guang-Hai YAN
3
Author Information
- Publication Type:Journal Article
- Keywords: asthma; DRP1; formononetin; inflammation; NLRP3; ROS
- From: Chinese Pharmacological Bulletin 2024;40(3):529-536
- CountryChina
- Language:Chinese
- Abstract: Aim To investigate the mechanism by which formononetin (FN) inhibits mitochondrial dynamic-related protein 1 (DRP1) -NLRP3 axis via intervening the generation of ROS to reduce allergic airway inflammation. Methods In order to establish allergic asthma mouse model, 50 BALB/c mice aged 8 weeks were divided into the control group, model group, FN treatment group and dexamethasone group after ovalbumin (OVA) induction. Airway inflammation and collagen deposition were detected by HampE and Masson staining. Th2 cytokines and superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), and IgE levels in bronchoalveolar lavage fluid (BALF) were measured by ELISA, ROS in BEAS-2B cells was assessed by DCFH-DA staining, DRP1 expression in lung tissue and BEAS-2B cells was detected by immunohistochemistry and immunofluorescence, and the DRP1-NLRP3 pathway was analyzed by immunoblotting. Results FN treatment could effectively ameliorate the symptoms of asthmatic mouse model, including reducing eosinophil accumulation, airway collagen deposition, decreasing Th2 cytokine and IgE levels, reducing ROS and MDA production, increasing SOD and CAT activities, and regulating DRP1-NLRP3 pathway-related protein expression, thereby relieving inflammation. Conclusion FN ameliorates airway inflammation in asthma by regulating DRP1-NLRP3 pathway.
